TPTX - TPTX STOCK NEWS

Turning Point Therapeutics (NASDAQ: TPTX) reported third-quarter financial results, highlighting a revenue of $25 million due to a licensing payment. Cash reserves stand at $711 million, bolstered by a recent stock offering generating $434 million, expected to fund operations through 2024.

Significant progress includes early data from the Phase 2 TRIDENT-1 study of repotrectinib, showing an 86% objective response rate in TKI-naïve ROS1-positive NSCLC patients. Upcoming milestones involve global site activation in early 2021 and further studies of TPX-0022.

Turning Point Therapeutics (NASDAQ: TPTX) announces that President and CEO Athena Countouriotis, M.D., will present at the Jefferies Virtual London Healthcare Conference on November 18 at 12:35 p.m. ET. The presentation will provide insights into the company's innovative pipeline, including their lead drug repotrectinib, which targets ROS1 and TRK drivers in lung cancer and other tumors. The session will be accessible via webcast on the company's Investors page. Turning Point is committed to developing precision oncology therapies to improve cancer treatment outcomes.

Turning Point Therapeutics (TPTX) has successfully closed its public offering of 5,287,357 shares at $87.00 each, raising approximately $460 million in gross proceeds. This includes the full exercise of an option for an additional 689,655 shares by underwriters. The offering was managed by Goldman Sachs, SVB Leerink, and Guggenheim Securities. The funds are intended to support the development of clinical-stage oncology therapies, including the company's lead candidate, repotrectinib, targeting cancer's genetic drivers.

Turning Point Therapeutics (TPTX) announced a public offering of 4,597,702 shares at $87.00 per share, aiming for gross proceeds of approximately $400 million. The underwriters have a 30-day option to purchase an additional 689,655 shares. The offering is set to close around October 29, 2020, subject to customary conditions. Goldman Sachs, SVB Leerink, and Guggenheim Securities are leading the offering, with shares offered under a previously effective shelf registration statement.

Turning Point Therapeutics (TPTX) has launched an underwritten public offering aiming to sell up to $400 million in common stock. The offering allows underwriters to purchase an additional 15% of the shares within 30 days. Goldman Sachs, SVB Leerink, and Guggenheim Securities are leading the offering. This initiative comes under a previously effective shelf registration statement with the SEC.

The company is focused on developing precision oncology therapies targeting genetic cancer drivers.

Turning Point Therapeutics (TPTX) announced preliminary clinical activity and safety profile results from its ongoing Phase 1 SHIELD-1 study of TPX-0022, a MET inhibitor. Initial findings show objective responses across multiple tumor types, with a tolerable safety profile. A total of 22 patients were treated, revealing promising efficacy, especially among MET TKI-naïve patients, with a partial response rate of 50%. The company plans to advance to a Phase 1 dose expansion and aims to discuss modifying the trial with the FDA, targeting Phase 2 initiation in late 2021.

Turning Point Therapeutics (NASDAQ: TPTX) has announced a conference call on October 24, 2020, at 11:00 a.m. ET to discuss initial data from its ongoing Phase 1 SHIELD-1 trial of TPX-0022, targeting MET signaling in cancer treatment. The data will be presented by Dr. David Hong during a late-breaking session at the EORTC-NCI-AACR Virtual Symposium. TPX-0022 is evaluated for safety and efficacy in patients with advanced solid tumors. The call can be accessed via the company's website or by phone.

Turning Point Therapeutics (NASDAQ: TPTX) announced that an abstract for its TRIDENT-1 clinical study of repotrectinib will be presented at the IASLC 2020 World Conference on Lung Cancer on January 31, 2021. Repotrectinib is a next-generation kinase inhibitor targeting oncogenic drivers in non-small cell lung cancer. The company is also advancing other drug candidates such as TPX-0022, TPX-0046, and TPX-0131 in various stages of clinical trials. Upcoming details on the presentation will be released on December 16, 2020, and January 12, 2021.

Turning Point Therapeutics (NASDAQ: TPTX) announced that two abstracts for its lead drug candidate repotrectinib have been selected for presentation at the Molecular Targets and Cancer Therapeutics symposium on October 24-25, 2020. The first abstract presents early clinical data for TPX-0022, a novel MET/SRC/CSF1R inhibitor, while the second highlights the efficacy of repotrectinib in enhancing KRAS-G12C inhibitor effectiveness and its anti-tumor activity in neuroblastoma models. The company continues its clinical studies, indicating ongoing development in precision oncology.